Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of milvexian after recent acute coronary syndrome
CTR20233529Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of milvexian in acute coronary syndrome (ACS), sponsored by Janssen Pharmaceutical. Started Nov 2023; status: terminated.
02
Drugs
milvexian
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on CTR20233529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233529.